Roivant Sciences Ltd. (ROIV) Misses Q3 EPS by 5c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
Go back to Roivant Sciences Ltd. (ROIV) Misses Q3 EPS by 5c, Revenues Beat
February 13, 2023 7:00 AM EST
$9.2M in net product revenue from VTAMA reported for the quarter ended December 31, 2022, with nearly 100,000 VTAMA prescriptions written by approximately 8,600 unique prescribers since launchVTAMA payor coverage significantly expanded, with 57% of commercial lives now coveredADORING 1 and 2 trials evaluating tapinarof in atopic dermatitis fully enrolled, with topline data expected from the first study in March 2023 and the second study in May 2023Partnership established with Pfizer to develop RVT-3101, a potentially first-in-class, fully human monoclonal antibody that blocks tumor necrosis factor-like ligand 1A (TL1A)Statistically significant and clinically meaningful efficacy results reported at... More
